Sandoz and Pear Therapeutics launch reSET for patients with substance use disorder.

Sandoz, a Novartis division, and Pear Therapeutics, Inc., announced the commercial launch of reSET for patients with Substance Use Disorder (SUD). reSET, the first and only FDA-authorized prescription digital therapeutic, is immediately available. To support patients and clinicians, Pear Therapeutics has also launched the reSET Connect Patient Service Center. A specialist is available to provide access to reSET, walk patients and clinicians through the steps for downloading and using reSET, troubleshoot any issues with reSET, and work with the patient's insurance company to ensure a seamless treatment experience.

ReSET is a 12-week (90-day) prescription digital therapeutic to be used in conjunction with outpatient clinician-delivered care. reSET offers interactive treatment modules that deliver cognitive behavioral therapy and fluency training to reinforce proficiency. Within the clinician dashboard, clinicians can follow patient-reported substance use, cravings, and triggers to facilitate transparency and deeper interaction between patients and clinicians at face-to-face meetings. .

Comment: In September 2018 the FDA granted a Novo request, allowing the Pear Therapeutics to market reSET for the treatment of patients with substance use disorder (SUD) under a new class of treatment. This is the first time that the FDA has cleared a Prescription Digital Therapeutic with claims to improve clinical outcomes in a disease.